Differential partitioning of Gαi1 with the cellular microtubules: a possible mechanism of development of Taxol resistance in human ovarian carcinoma cells

Por Parekh, Hemant K, Adikari, Mahesha, Vennapusa, Bharathi
Publicado em 2006

Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N

Por Smith, Jacquelyn, Robida, Mark D., Acosta, Krista, Vennapusa, Bharathi, Mistry, Amita, Martin, Greg, Yates, Alton, Hnatyszyn, H. James
Publicado no Diagn Pathol (2016)

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma

Por Kaseb, Ahmed Omar, Hassan, Manal, Lacin, Sahin, Abdel-Wahab, Reham, Amin, Hesham M., Shalaby, Ahmed, Wolff, Robert A., Yao, James, Rashid, Asif, Vennapusa, Bharathi, Feng, Janine, Ohtomo, Toshihiko
Publicado no Oncotarget (2016)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Por Vennapusa, Bharathi, Baker, Brian, Kowanetz, Marcin, Boone, Jennifer, Menzl, Ina, Bruey, Jean-Marie, Fine, Gregg, Mariathasan, Sanjeev, McCaffery, Ian, Mocci, Simonetta, Rost, Sandra, Smith, Dustin, Dennis, Eslie, Tang, Szu-Yu, Damadzadeh, Bita, Walker, Espen, Hegde, Priti S., Williams, J. Andrew, Koeppen, Hartmut, Boyd, Zachary
Publicado no Appl Immunohistochem Mol Morphol (2019)

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Por Rudin, Charles M, Pietanza, M Catherine, Bauer, Todd M, Ready, Neal, Morgensztern, Daniel, Glisson, Bonnie S, Byers, Lauren A, Johnson, Melissa L, Burris, Howard A, Robert, Francisco, Han, Tae H, Bheddah, Sheila, Theiss, Noah, Watson, Sky, Mathur, Deepan, Vennapusa, Bharathi, Zayed, Hany, Lally, Satwant, Strickland, Donald K, Govindan, Ramaswamy, Dylla, Scott J, Peng, Stanford L, Spigel, David R
Publicado no Lancet Oncol (2016)